ORIGINAL ARTICLE |
|
Year : 2017 | Volume
: 23
| Issue : 6 | Page : 348-356 |
|
Validity and clinical impact of glucose transporter 1 expression in colorectal cancer
Ghada M. K GabAllah1, Mona Salah El-din Habib1, Shimaa El-Shafey Soliman1, Zienab A Kasemy2, Suzy F Gohar3
1 Department of Medical Biochemistry, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt 2 Department of Public Health and Community Medicine, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt 3 Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt
Correspondence Address:
Suzy F Gohar Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Shibin El Kom Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/sjg.SJG_197_17
|
|
Background/Aim: There is no doubt that colorectal cancer (CRC) poses a major threat to public health worldwide, and despite improvement in managements, prognosis still remains an irritating question with no definite answer. Being a fundamental player in cancer metabolism, glucose transporter 1 (GLUT1) could be utilized as a prognostic biomarker that could fuel development of new treatment strategies. The aim of this study was to assess the validity of GLUT1 expression as a prognostic biomarker and to elucidate to what extent it is immersed in poor clinical outcome among CRC patients.
Patients and Methods: GLUT1 expression in peripheral blood specimens was analyzed by quantitative real-time polymerase chain reaction in 47 CRC patients and 20 healthy controls.
Results: There was significantly elevated GLUT1 expression in peripheral blood of CRC patients than in controls (P < 0.001). The cutoff value of 0.605 provided 98% sensitivity and 100% specificity. There were significantly higher values of GLUT1 expression in patients under 50 years (P = 0.003), performance status 2 (P = 0.009), stage IV (P < 0.001), and presence of metastasis (P < 0.001). GLUT1 expression showed nonsignificant association with overall survival (P = 0.068), while tumor stage (P = 0.01) and metastasis (P = 0.009) were significantly associated with lower overall survival.
Conclusion: GLUT1 is sensitive and specific marker for CRC. It is overexpressed in young age patients, poor performance status, and stage IV patients. Although this was not statistically significant, GLUT 1 showed higher expression level in patients with lesser survival.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|